IL157701A0 - N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same - Google Patents

N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same

Info

Publication number
IL157701A0
IL157701A0 IL15770102A IL15770102A IL157701A0 IL 157701 A0 IL157701 A0 IL 157701A0 IL 15770102 A IL15770102 A IL 15770102A IL 15770102 A IL15770102 A IL 15770102A IL 157701 A0 IL157701 A0 IL 157701A0
Authority
IL
Israel
Prior art keywords
compound
methyl
processes
producing
active ingredient
Prior art date
Application number
IL15770102A
Other languages
English (en)
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of IL157701A0 publication Critical patent/IL157701A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
IL15770102A 2001-03-12 2002-03-11 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same IL157701A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001068498 2001-03-12
JP2001281569 2001-09-17
JP2002007760 2002-01-16
PCT/JP2002/002245 WO2002072564A1 (fr) 2001-03-12 2002-03-11 Compose de n-phenylarylsulfonamide, medicament contenant le compose en tant que principe actif, intermediaire pour le compose et ses procedes de production

Publications (1)

Publication Number Publication Date
IL157701A0 true IL157701A0 (en) 2004-03-28

Family

ID=27346214

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15770102A IL157701A0 (en) 2001-03-12 2002-03-11 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
IL157701A IL157701A (en) 2001-03-12 2003-09-02 N-compound - Phenylarylsulfonamide and pharmaceutical preparations containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157701A IL157701A (en) 2001-03-12 2003-09-02 N-compound - Phenylarylsulfonamide and pharmaceutical preparations containing them

Country Status (24)

Country Link
US (3) US7235667B2 (fr)
EP (2) EP1612208B1 (fr)
JP (3) JP3555620B2 (fr)
KR (1) KR100886854B1 (fr)
CN (1) CN1294126C (fr)
AT (2) ATE522513T1 (fr)
AU (1) AU2002238855B2 (fr)
BR (1) BR0208027A (fr)
CA (1) CA2439604C (fr)
CZ (1) CZ304035B6 (fr)
DE (1) DE60220255T2 (fr)
DK (2) DK1369419T3 (fr)
ES (1) ES2286230T3 (fr)
HU (1) HU230056B1 (fr)
IL (2) IL157701A0 (fr)
MX (1) MXPA03008134A (fr)
NO (1) NO329682B1 (fr)
NZ (1) NZ528120A (fr)
PL (1) PL218750B1 (fr)
PT (2) PT1612208E (fr)
RU (1) RU2299202C2 (fr)
TW (1) TWI317359B (fr)
WO (1) WO2002072564A1 (fr)
ZA (1) ZA200306884B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003264388A1 (en) * 2002-09-09 2004-03-29 Ono Pharmaceutical Co., Ltd. Process for producing 4-methyl-1,3-thiazol-2-ylsulfonyl halide
DK1603893T3 (da) * 2003-01-29 2008-09-08 Asterand Uk Ltd EP4 -Receptorantagonister
GB0317500D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Treatment of bph
WO2005000356A1 (fr) * 2003-06-27 2005-01-06 Ono Pharmaceutical Co., Ltd. Remede contre des maladies des voies urinaires
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2006004115A1 (fr) * 2004-07-05 2006-01-12 Chugai Seiyaku Kabushiki Kaisha Remède pour vessie hyperactive
JP2008189549A (ja) * 2005-05-12 2008-08-21 Astellas Pharma Inc カルボン酸誘導体またはその塩
JP2009057282A (ja) * 2005-12-19 2009-03-19 Astellas Pharma Inc カルボン酸誘導体又はその塩
TW200817319A (en) * 2006-08-10 2008-04-16 Astellas Pharma Inc Sulfonamide compound or salt thereof
JP5439817B2 (ja) 2007-02-16 2014-03-12 小野薬品工業株式会社 尿排出障害治療剤
PT2177512E (pt) * 2007-08-01 2012-05-07 Taisho Pharmaceutical Co Ltd Inibidor da ligação de s1p1
SG157299A1 (en) * 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
JP5304785B2 (ja) * 2008-06-23 2013-10-02 アステラス製薬株式会社 スルホンアミド化合物又はその塩
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
US8916553B2 (en) 2010-07-26 2014-12-23 Bristol-Myers Squibb Company Sulfonamide compounds useful as CYP17 inhibitors
JP5363636B2 (ja) * 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
US20140039004A1 (en) * 2012-07-31 2014-02-06 Ono Pharmaceutical Co., Ltd. Method of treating of gastroesophageal reflux disease
JP6103893B2 (ja) * 2012-11-15 2017-03-29 サントリー食品インターナショナル株式会社 コーヒーオイルの製造方法
PT3138633T (pt) * 2014-04-30 2019-02-01 Ind Penalver Sl Cabeça concêntrica programável para aplicação de líquido em tampas de diferentes formatos
ES2821962T3 (es) * 2015-11-13 2021-04-28 Dae Woong Pharma Bloqueador de canales de sodio
RU2659955C1 (ru) * 2017-10-26 2018-07-04 Галина Ильхамовна Лукина Способ диагностики высоких гастроэзофагеальных рефлюксов

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5748534B2 (fr) 1974-03-04 1982-10-16
DE2419923A1 (de) * 1973-04-28 1974-11-28 Fujisawa Pharmaceutical Co Sulfonsaeureester, verfahren zu deren herstellung und verwendung derselben als kondensationsmittel
DE2555048A1 (de) * 1975-12-06 1977-06-30 Pfersee Chem Fab Verfahren und vorrichtung zur herstellung bestaendiger, waessriger emulsionen wasserunloeslicher substanzen
JPS5293469A (en) 1976-02-02 1977-08-05 Fuji Photo Film Co Ltd Method of curing gelatin
JPH05293469A (ja) 1992-04-17 1993-11-09 Toda Constr Co Ltd 滅菌精製水の製造方法およびその装置
TW523506B (en) * 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
AU4431400A (en) * 1999-05-12 2000-12-05 Japan As Represented By President Of National Cancer Center Anticancer agents containing ep1 antagonists as the active ingredient
KR20020012639A (ko) 1999-07-29 2002-02-19 우에노 도시오 술폰아미드 유도체 및 알로디니아 치료제
KR20030081520A (ko) * 2001-03-14 2003-10-17 오노 야꾸힝 고교 가부시키가이샤 Ep1 안타고니스트를 유효 성분으로서 함유하는 울병의치료제

Also Published As

Publication number Publication date
ZA200306884B (en) 2005-03-30
NO20034007L (no) 2003-11-12
CZ304035B6 (cs) 2013-08-28
DK1369419T3 (da) 2007-09-24
JP3555620B2 (ja) 2004-08-18
PT1369419E (pt) 2007-08-16
CN1509278A (zh) 2004-06-30
ATE362924T1 (de) 2007-06-15
DK1612208T3 (da) 2011-12-12
IL157701A (en) 2010-06-30
HUP0400155A2 (hu) 2004-08-30
CN1294126C (zh) 2007-01-10
CZ20032452A3 (cs) 2003-11-12
PT1612208E (pt) 2011-10-12
RU2299202C2 (ru) 2007-05-20
HU230056B1 (hu) 2015-06-29
HUP0400155A3 (en) 2007-05-02
CA2439604A1 (fr) 2002-09-19
DE60220255T2 (de) 2008-01-17
KR20030082978A (ko) 2003-10-23
MXPA03008134A (es) 2004-03-10
EP1612208B1 (fr) 2011-08-31
JP2004149545A (ja) 2004-05-27
EP1369419B1 (fr) 2007-05-23
PL218750B1 (pl) 2015-01-30
JP2006028193A (ja) 2006-02-02
DE60220255D1 (de) 2007-07-05
TWI317359B (en) 2009-11-21
EP1369419A4 (fr) 2005-03-16
NO20034007D0 (no) 2003-09-10
NO329682B1 (no) 2010-11-29
EP1612208A2 (fr) 2006-01-04
US20060030713A1 (en) 2006-02-09
WO2002072564A1 (fr) 2002-09-19
ES2286230T3 (es) 2007-12-01
JP3741120B2 (ja) 2006-02-01
EP1612208A3 (fr) 2006-12-06
BR0208027A (pt) 2004-12-28
NZ528120A (en) 2006-05-26
PL365100A1 (en) 2004-12-27
US20050124672A1 (en) 2005-06-09
US8088802B2 (en) 2012-01-03
US7235667B2 (en) 2007-06-26
EP1369419A1 (fr) 2003-12-10
RU2003127677A (ru) 2005-03-27
CA2439604C (fr) 2012-05-01
ATE522513T1 (de) 2011-09-15
JP4432051B2 (ja) 2010-03-17
JPWO2002072564A1 (ja) 2004-07-02
US7629369B2 (en) 2009-12-08
AU2002238855B2 (en) 2007-12-06
US20100041708A1 (en) 2010-02-18
KR100886854B1 (ko) 2009-03-05

Similar Documents

Publication Publication Date Title
IL157701A0 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
NZ514661A (en) alpha-substituted carboxylic acid derivatives and their use as therapeutic agents in pharmaceutical compositions
DE60018064D1 (de) Substituierte phenylpropionsäurederivate als agonisten des menschlichen peroxisom-proliferator-aktiverten rezeptors alpha(ppar)
NO20032510L (no) Organiske forbindelser
JP2003501361A5 (fr)
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
WO2002085861A8 (fr) Composes d'imidazolidine et leur utilisation comme antagonistes de cxcr3
WO2003063791A3 (fr) Analogues non steroidiens de 2-methoxyestradiol
CA2280310A1 (fr) Antagoniste de nmda
CA2518971A1 (fr) Composition pour l'administration de fer traitant le syndrome des jambes sans repos
HK1045464A1 (en) Use of sulfodehydroabietic acid for the treatment of inflammatory bowel disease
WO2003008365A3 (fr) Derives de phenylacetamido-thiazole, leur procede de preparation et leur utilisation en tant qu'agents antitumoraux
NO20023551L (no) Ibuprofen-inneholdende aktivt middel-preparat
Yu et al. Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters
WO2007127421A3 (fr) Synthèse de (+) et (-)-1-aryl-3-azabicyclo[3.1.0]hexanes
WO1999004770A3 (fr) Composition pharmaceutique active dans la reduction de production de proteine mcp-1
WO2003018010A1 (fr) Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose
MXPA01007210A (es) Agente para el tratamiento de enfermedad de parkinson que comprende un agente que mejora la funcion del astrocito como ingrediente activo.
ZA993528B (en) A compound for use in treating glaucoma and ischemic retinopathy.